Antimicrobial activity of nitrofurans (nitrofurantoin, furazidine and furazidine potassium) against uropatogenic Escherichia coli isolated from patients with lower urinary tract infections

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Currently, the problem of antibiotic resistance is of great relevance to society not only for medical, but also for social and economic reasons. Infections caused by multidrug-resistant pathogens have a longer course, more often require hospitalization, and increase the risk of mortality. The antimicrobial resistance is most relevant for hospitals in the case of the development of nosocomial infections. However, in recent years in Russia and Europe, resistant microorganisms have become more often found in patients with community-acquired urinary tract infections. In this review, we present data from two recent large Russian studies on antibiotic resistance of community-acquired strains of uropathogens and a microbiological study carried out in Switzerland to study the antimicrobial activity of furazidin, soluble furazidin, nitrofurantoin and ciprofloxacin. For the first time, an evaluation of the antimicrobial activity of soluble furazidin allowed to explain the high clinical efficiency of furazidin potassium, documented in trials and real clinical practice. This study, in line with Russian data, indicates the high activity of nitrofurans against Escherichia coli, the main causative agent of UTI.

Full Text

Restricted Access

About the authors

S. V. Yakovlev

FGAOU VO I.M. Sechenov First Moscow State Medical University

Author for correspondence.
Email: antimicrob@yandex.ru
ORCID iD: 0000-0001-7606-8608

Ph.D., MD, professor at the Department of Internal Medicine №2 of Institute of the Clinical Medicine named after N.V. Sklifosovsky

Russian Federation, Moscow

Z. K. Gadzhieva

FGAOU VO I.M. Sechenov First Moscow State Medical University

Email: gadzhieva_z_k@staff.sechenov.ru

Ph.D., MD, Head of the Department of analysis of personnel policy, educational programs and scientific research of the National Medical Research Center for «Urology», deputy Executive Director of the Russian Society of Urology, scientific editor of the journal “Urologiia”

Russian Federation, Moscow

M. P. Suvorova

FGAOU VO I.M. Sechenov First Moscow State Medical University

Email: margarita-suv@yandex.ru
ORCID iD: 0000-0002-1389-6454

Ph.D., associate professor at the Department of Internal Medicine №2 of Institute of the Clinical Medicine named after N.V. Sklifosovsky

Russian Federation, Moscow

References

  1. Roberts R.R., Hota B., Ahmad I., et al. Hospital and social costs of antimicrobial-resistant infections in a Chicago teaching hospital:implications for antibiotic stewardship. Clin Infect Dis. 2009;49:1175–1184.
  2. Yakovlev S.V. A new concept of the rational use of antibiotics in outpatient practice. Antibiotics and chemotherapy. 2019;64(3–4):48–58. Russian (Яковлев С.В. Новая концепция рационального применения антибиотиков в амбулаторной практике. Антибиотики и химиотерапия. 2019;64(3–4):48–58).
  3. Ferri M., Ranucci E., Romagnoli P., Giaccone V. Antimicrobial resistance: A global emerging threat to public health systems. Crit Rev Food Sci Nutr. 2017;57(13):2857–2876. doi: 10.1080/10408398.2015.1077192.
  4. Naboka Y.L., Kogan M.I., Chernitskaya M.L. and others. The microbial spectrum of prostate secretion and bacterial persistence factors found in chronic bacterial prostatitis. Bulletin of the Orenburg Scientific Center of the Ural Branch of the Russian Academy of Sciences. 2012;3:11. Russian (Набока Ю.Л., Коган М.И., Черницкая М.Л. и др. Микробный спектр секрета предстательной железы и факторы персистенции бактерий, обнаруженных при хроническом бактериальном простатите. Бюллетень Оренбургского научного центра УрО РАН. 2012;3:11).
  5. Alyaev Yu.G., Arefyeva O.A., Asfandiyarov F.R. and others. Infections and inflammation in urology. Moscow: Medforum, 2019. 888 p. ISBN 978-5-9500559-5-9. EDN PKAWUH. Russian (Аляев Ю.Г., Арефьева О.А., Асфандияров Ф.Р. и др. Инфекции и воспаления в урологии. М.: Медфорум, 2019. 888 с. ISBN 978-5-9500559-5-9. EDN PKAWUH).
  6. Shangichev A.V., Naboka Y.L., Ibishev X.S., Kogan M.I. Microbial spectrum and antibiotic sensitivity of microorganisms of prostate secretion in chronic bacterial prostatitis. Kuban Scientific Medical Bulletin. 2010;3–4(117–118):207–211. EDN MUMCOJ. Russian (Шангичев А.В., Набока Ю.Л., Ибишев X.С., Коган М.И. Микробный спектр и антибиотикочувствительность микроорганизмов секрета простаты при хроническом бактериальном простатите. Кубанский научный медицинский вестник. 2010;3–4(117–118):207–211. EDN MUMCOJ).
  7. Ibishev H.S., Malinovskaya V.V., Parfenov V.V. Treatment of persistent infection of the lower urinary tract in women. The attending physician. 2014;9:90 a.m. EDN SNXUGT. Russian (Ибишев Х.С., Малиновская В.В., Парфенов В.В. Лечение персистирующей инфекции нижних мочевых путей у женщин. Лечащий врач. 2014;9:90. EDN SNXUGT).
  8. Коган М.И., Ибишев Х.С., Набока Ю.Л. и др. Расширенное бактериологическое исследование как ключ к пересмотру антибактериальной терапии хронического бактериального простатита / // Урология. – 2023. – № 1. – С. 5–11. – doi: 10.18565/urology.2023.1.5-11. – EDN JDVBJS.
  9. Antimicrobial Resistance Global Report on surveillance. Webcast of Q-A Session on global report on surveillance, 2014 (http://apps.who.int/iris/bitstream/10665/112642/1/9789241564748_eng.pdf?ua=1).
  10. Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet. 2022 Feb 12;399(10325):629–655. Вoi: 10.1016/S0140-6736(21)02724-0.
  11. Li Xю, Fan Hю, Zi Hю, Hu Hю, Li Bю, Huang Jю, Luo Pю, Zeng X. Global and Regional Burden of Bacterial Antimicrobial Resistance in Urinary Tract Infections in 2019. J Clin Med. 2022 May 17;11(10):2817. doi: 10.3390/jcm11102817.
  12. Palagin I.S., Sukhorukova M.V., Dekhnich A.V., et al. DARMIS Study Group. Antimicrobial resistance of pathogens causing community-acquired urinary tract infections in Russia: results of the multicenter study “DARMIS-2018”. Klinicheskaja mikrobiologija i antimikrobnaja himioterapija. 2019;21(2):134–146. Russian (Палагин И.С., Сухорукова М.В., Дехнич А.В. и соавт. Антибиотикорезистентность возбудителей внебольничных инфекций мочевыводящих путей в России: результаты многоцентрового исследования «ДАРМИС-2018». Клиническая микробиология и антимикробная химиотерапия 2019;21(2):134–146).
  13. Rafalskiy V., Pushkar D., Yakovlev S., Epstein O., Putilovskiy M., Tarasov S., Glazunov A., Korenev S., Moiseeva E., Gorelysheva N. Distribution and antibiotic resistance profile of key Gram-negative bacteria that cause community-onset urinary tract infections in the Russian Federation: RESOURCE multicentre surveillance 2017 study. J Glob Antimicrob Resist. 2020;21:188–194. doi: 10.1016/j.jgar.2019.09.008.
  14. Hooton T.M. Clinical practice. Uncomplicated urinary tract infection. N Engl J Med. 2012;366(11):1028–1037. doi: 10.1056/NEJMcp1104429.
  15. Yakovlev S.V., Suvorova M.P. [Rationale for choosing an antibiotic for the treatment of cystitis: recommendations of clinical pharmacologists: A review]. Ter Arkh. 2022;94(8):1006–1013. Russian (Яковлев С.В., Суворова М.П. Обоснование выбора антибиотика для лечения цистита: рекомендации клинических фармакологов. Обзор литературы. Терапевтический архив. 2022;94(8):1006–1013. doi: 10.26442/00403660.2022.08.201775).
  16. Stratchounski L.S., Rafalski V.V. Antimicrobial susceptibility of pathogens isolated from adult patients with uncomplicated community-acquired urinary tract infections in the Russian Federation: two multicentre studies, UTIAP-1 and UTIAP-2. Int J Antimicrob Agents. 2006;28 Suppl 1:S4–9.
  17. Schito G.C., Naber K.G., Botto H., Palou J., Mazzei T., Gualco L., Marchese A. The ARESC study: an international survey on the antimicrobial resistance of pathogens involved in uncomplicated urinary tract infections. Int J Antimicrob Agents. 2009;34(5):407–413. doi: 10.1016/j.ijantimicag.2009.04.012.
  18. Naber K.G., Bishop M.C., Bjerklund-Johansen T.E., et al. Guidelines on the management of urinary and male genital tract infections. European association of Urology. 2006. www.uroweb.org.
  19. Bonkat G., Bartoletti R., Bruyère F., Cai T., Geerlings S.E., Köves B, Kranz, S. Schubert, A. Pilatz, R. Veeratterapillay, F. Wagenlehner. EAU Guidelines on urological infections. European Association of Urology 2024. https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-Guidelines-on-Urological-Infections-2024.pdf
  20. Bacterial cystitis in adults. Clinical recommendations. The Ministry of Health of the Russian Federation. 2021 https://cr.minzdrav.gov.ru. Russian (Цистит бактериальный у взрослых. Клинические рекомендации. Министерство здравоохранения РФ. 2021 г. https://cr.minzdrav.gov.ru/).
  21. Mahdizade Ari M., Dashtbin S., Ghasemi F., Shahroodian S., Kiani P., Bafandeh E., Darbandi T., Ghanavati R., Darbandi A. Nitrofurantoin: properties and potential in treatment of urinary tract infection: a narrative review. Front Cell Infect Microbiol. 2023;13:1148603. doi: 10.3389/fcimb.2023.1148603.
  22. Яковлев С.В., Суворова М.П. Обоснование выбора антибиотика при инфекциях мочевыводящих путей с акцентом на экологическую безопасность антибактериальной терапии. Урология. 2021;4:97–105. Doi: https://dx.doi.org/10.18565/urology.2021.4.97-105. Russian (Yakovlev SV, Suvorova MP. [Rationale for the choice of an antibiotic for urinary tract infections with an emphasis on the environmental safety of therapy]. Urologiia. 2021;(4):97–105).
  23. Huttner A., Verhaegh E.M., Harbarth S., Muller A.E., Theuretzbacher U., Mouton J.W. Nitrofurantoin revisited: a systematic review and meta-analysis of controlled trials. J Antimicrob Chemother. 2015;70(9):2456–2464. doi: 10.1093/jac/dkv147.
  24. Muller A.E., Verhaegh E.M., Harbarth S., Mouton J.W., Huttner A. Nitrofurantoin’s efficacy and safety as prophylaxis for urinary tract infections: a systematic review of the literature and meta-analysis of controlled trials. Clin Microbiol Infect. 2017;23(6):355–362. doi: 10.1016/j.cmi.2016.08.003.
  25. Mahdizade Ari M., Dashtbin S., Ghasemi F., Shahroodian S., Kiani P., Bafandeh E., Darbandi T., Ghanavati R., Darbandi A. Nitrofurantoin: properties and potential in treatment of urinary tract infection: a narrative review. Front Cell Infect Microbiol. 2023;13:1148603. doi: 10.3389/fcimb.2023.1148603.
  26. Stein G.E. Comparison of single-dose fosfomycin and a 7-day course of nitrofurantoin in female patients with uncomplicated urinary tract infection. Clin Ther. 1999;21(11):1864–1872. doi: 10.1016/S0149-2918(00)86734-X.
  27. Huttner A., Kowalczyk A., Turjeman A., Babich T., Brossier C., Eliakim-Raz N., Kosiek K., Martinez de Tejada B., Roux X., Shiber S., Theuretzbacher U., von Dach E., Yahav D., Leibovici L., Godycki-Cwirko M., Mouton J.W., Harbarth S. Effect of 5-Day Nitrofurantoin Perepanova T.S. Nitrofurans in the urological practice: are they all the same and why are we getting back to them today? Experimental and clinical urology. 2018(3)91–101. Russian Tract Infection in Women: A Randomized Clinical Trial. JAMA. 2018;319(17):1781–1789. doi: 10.1001/jama.2018.3627.
  28. Hendriks-Spoor K.D., Wille F.L., Doesschate T.T., Dorigo-Zetsma J.W. Verheij T.J.M., van Werkhoven C.H. Five versus seven days of nitrofurantoin for urinary tract infections in women with diabetes: a retrospective cohort study. Clin Microbiol Infect. 2022;28(3):377–382. doi: 10.1016/j.cmi.2021.06.034.
  29. Bronskaya G.M., Vdovichenko V.P., Korshak T.A., Dybov O.G., Sak E.N. Nitrofurans in the treatment for urinary tract infections. Health and Ecology Issues. 2011;(2):28-32. Russian (Бронская Г.М., Вдовиченко В.П., Коршак Т.А., Дыбов О.Г., Сак Е.Н. Нитрофураны в лечении инфекций мочевыводящих путей. Проблемы здоровья и экологии. 2011;(2):28–32. doi: 10.51523/2708-6011.2011-8-2-5).
  30. Perepanova T.S. Nitrofurans in the urological practice: are they all the same and why are we getting back to them today? Experimental and clinical urology. 2018(3)91–101. Russian (Перепанова Т.С. Нитрофураны в урологической практике: все ли они одинаковые и почему мы возвращаемся к ним сегодня? Экспериментальная и клиническая урология. 2018(3)91–101).
  31. The State Register of Medicines. Instructions for the medical use of the drug Furamag®, capsules, 25 mg, LSR-002179/08 (JSC «Olainfarm», Latvia). Russian (Государственный реестр лекарственных средств. Инструкция по медицинскому применению лекарственного препарата Фурамаг®, капсулы, 25 мг, ЛСР-002179/08 (АО «Олайнфарм», Латвия).
  32. Padejskaja E.N. Furamag among antimicrobial drugs derived from 5-nitrofuran: implications for clinical practice. Infections and Antimicrobial Therapy. 2004;6(1):24–31. Russian (Падейская Е.Н. Фурамаг в ряду антимикробных препаратов, производных 5-нитрофурана: значение для клинической практики. Инфекции и антимикробная терапия. 2004;6(1):24–31).
  33. Ramenskaya G.V. The study of comparative pharmacokinetics of furamag and furagin. Infections and Antimicrobial Therapy. 2004;6(1):34–37. Russian (Раменская Г.В. Изучение сравнительной фармакокинетики препаратов фурамаг и фурагин. Инфекции и антимикробная терапия. 2004;6(1):34–37).
  34. Yakovlev S.V., Logvinov L.A. Klochkov I.A., Polikarpova S.V., Panin A.G., Kovyrshina L.A. and coauthors. Clinical and bacteriological efficacy of the drug «Furamag» in patients with acute cystitis. Infections and antimicrobial therapy. 2005;7(4):120–126. Russian (Яковлев С.В., Логвинов Л.А. Клочков И.А., Поликарпова С.В., Панин А.Г., Ковыршина Л.А. и соавт. Клиническая и бактериологическая эффективность препарата «Фурамаг» у пациентов с острым циститом. Инфекции и антимикробная терапия. 2005;7(4):120–126).
  35. https://www.eucast.org/mic_distributions_and_ecoffs/
  36. Data on File. Determination of Minimum Inhibitory Concentration (MIC) for furagin, furaginum solubile, ciprofloxacin, and nitrofurantoin against recent clinical isolates. IHMA Europe Sárl – Report study 3573.
  37. Neĭmark A.I., Simashkevich A.V. [Use of furamag to prevent inflammatory complications during endoscopic operations in patients with benign prostatic hyperplasia and urolithiasis]. Ter Arkh. 2012;84(10):62–64. Russian (Неймарк А.И., Симашкевич А.В. Применение препарата фурамаг для профилактики воспалительных осложнений во время эндоскопических операций у пациентов с доброкачественной гиперплазией предстательной железы и уролитиазом. Терапевтический архив. 2012;84(10):62–64).
  38. Clinical efficacy of antimicrobial drug furamag in hospital urinary tract infections. Ter Arkh. 2014;10:65-72. Russian (Яковлев С.В., Суворова М.П., Колендо С.Е., и др. Клиническая эффективность антимикробного препарата фурамаг при больничных инфекциях мочевыводящих путей. Терапевтический архив 2014;10:65–72).
  39. Ovcharenko L.S., Vertegel A.A., Andrienko T.G., Samokhin I.V., Kryazhev O.V., Sheludko D.N. Therapy of recurrent urinary tract infection in children with assessment of the uropathogens sensitivity profile. Sovremennaya pediatriya. 2017.1(81):34–38. doi: 10.15574/SP.2017.81.34. Russian (Овчаренко Л.С., Вертегел А.А., Андриенко Т.Г., Самохин И.В., Кряжев О.В., Шелудько Д.Н. Терапия повторных эпизодов инфекции мочевыделительной системы у детей с оценкой профиля чувствительности уропатогенов. Современная педиатрия. 2017;1(81):34–38).
  40. Strazdins V., Cernevskis H. Recurrent Urinary Tract Infection in Adults in Latvia: 2014 Observational Study. J Nephrol Ther. 2015,5:4. http://dx.doi.org/10.4172/2161-0959.1000208

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Figure. Resistance to oral antibiotics of community-acquired strains of uropathogenic Escherichia coli isolated from patients with uncomplicated (nIMVP) and complicated (AML) urinary tract infections in Russia: studies by DARMIS 2017-18 [12] and RESOURCE 2017 [13]. The EUCAST criteria were used to assess antibiotic resistance [35]. Nitrofurantoin criteria were used for furazidine

Download (220KB)
Indexing metadata

Copyright (c) 2024 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies